Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the potential utility of monitoring minimal residual disease (MRD) in patients with colorectal cancer. For patients who are circulating tumor DNA (ctDNA) positive, there is no standard of care, and there are various programs and trials underway to elucidate the optimal treatment sequence in this MRD setting. However, the link between ctDNA clearance and overall survival needs to be further investigated. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.